GH Research/$GHRS

1D1W1MYTD1Y5YMAX

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Ticker
$GHRS
Sector
Health
Primary listing
NASDAQ
Employees
73
Headquarters
Dublin, Ireland
Website
www.ghres.com

GH Research Metrics

BasicAdvanced
$1.6B
-
-$0.99
1.28
-

What the Analysts think about GH Research

Analyst ratings (Buy, Hold, Sell) for GH Research stock.
Analyst projections of the future price of GH Research stock.

Bulls say / Bears say

GH001 produced a large and rapid effect in the Phase 2b trial: a 15.5-point placebo-adjusted MADRS improvement at Day 8, with 57.5% of treated patients in remission versus none on placebo. The result was published in JAMA Psychiatry, giving the lead programme stronger clinical credibility as it moves towards Phase 3. (JAMA Psychiatry)
The development programme has cleared several practical hurdles before pivotal testing. GH Research says it completed two Phase 1 studies, selected Phase 3 doses, and received FDA feedback that its manufacturing and inhaler-device plans appear Phase 3 ready. (GH Research)
GH Research had $362.7 million in cash, cash equivalents and marketable securities at 30 June 2026, following a $117.5 million equity raise. That balance gives the company a useful funding buffer as it starts the expensive global Phase 3 programme, reducing near-term financing pressure. (GH Research, GH Research)
The encouraging Phase 2b evidence came from only 81 randomised patients, while the longer follow-up was open-label and had 63 completers. A larger Phase 3 trial could therefore produce a less impressive efficacy or durability result than the early data suggest. (JAMA Psychiatry)
GH Research remains pre-revenue and loss-making: Q2 net loss was $15.15 million and the six-month loss was $34.11 million. Rising trial spending means the company may eventually need further equity funding, creating dilution risk even after the recent raise. (Simply Wall St, GH Research)
Psychedelic medicines still face demanding implementation and regulatory questions around patient screening, monitoring, provider training, access and long-term safety. These unresolved requirements could slow GH001’s path to approval or make commercial rollout more complex and costly than the clinical results alone imply. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.

GH Research Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

GH Research Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

GH Research News

AllArticlesVideos

Why Is GH Research Stock Trading Higher on Thursday?

Benzinga2 months ago

Funds containing GH Research

AllUSDGBP
Funds
Fund name
Fund size
$GHRS weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.11%
iShares Nasdaq US Biotechnology£BTEK
£865M0.11%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.